To this aim, we used an experimental model of thioacetamide (TAA)-induced liver fibrosis, modulating the activity of AMP-activated protein kinase (AMPK)/Sirtuin-1 (SIRT-1) and inhibiting hypoxia-inducible factor 1-alpha (HIF-1α). The gene discussed is HIF1A; the disease is Hepatic fibrosis.